Friedreich's ataxia, characterized by decreased expression of frataxin protein, is caused by GAA trinucleotide repeats within intron 1 in 98% of patients. Two percent of patients carry GAA repeats in conjunction with a point mutation. In this work, we find that frataxin W168R , a novel disease-causing missense mutation, is expressed predominantly as the intermediate frataxin form, with very little expression of mature frataxin form. Its localization to mitochondria is not impaired. Additionally, increasing frataxin W168R precursor levels do not lead to an increase in mature frataxin levels, suggesting these patients will require alternative approaches to repair frataxin processing in order to treat the disorder in a disease-modifying manner.
Introduction
Friedreich's Ataxia (FRDA), which affects about 1 in every 50,000 people in the United States, is a slowly progressive ataxia with symptoms including dysarthria, spasticity in the lower limbs, cardiomyopathy, scoliosis, absent lower limb reflexes, and loss of position and vibration sense. [1] [2] [3] At present there is no cure or effective treatment for FRDA. Typical FRDA is characterized by decreased expression of the frataxin (FXN) protein, from the FXN gene on chromosome 9, caused by the presence of expanded GAA trinucleotide repeats within intron 1. Frataxin is crucial for proper mitochondria function and iron-sulfur cluster biogenesis, but the mechanism by which decreased protein expression leads to disease pathology is not fully known. Ninety percent of patients carry GAA expansions on both alleles in which the length of the allele with the shortest GAA expansion correlates with disease severity; longer alleles result in earlier onset and a faster progression. [4] [5] [6] In contrast, 2-4% of patients carry expanded GAA repeats on one allele, and a point mutation on the other allele. These patients generally have lower FXN levels compared to typical FRDA patients. 7, 8 As intronic, nonsense, and frame shift point mutations lead to absence of functional frataxin, [9] [10] [11] [12] [13] [14] the phenotype in such patients is usually severe. In contrast patients with missense mutations can have a mild or severe clinical outcome depending on the exact mutation and the length of the GAA repeat on the opposite allele. [9] [10] [11] 15, 16 The full-length precursor (FXN ) is processed by mitochondrial processing peptidase to intermediate ) and mature (FXN ) forms. Many different missense mutations have been described in patients with FRDA, and some of which lead to the absence of functional protein. In contrast, the G130V mutation, generally associated with a milder phenotype, is associated with incomplete processing of frataxin to its mature form. 8 In vitro studies allow one to distinguish between those affecting frataxin processing and those altering overall levels (due to folding, RNA splicing or other severely pathogenic processes), and show that the specific location of missense mutations within the protein structure affects folding of frataxin into a native conformation (L106S) 9,12-14 and decreases participation in iron-sulfur cluster biogenesis (R165C, W155R), which is hypothesized to be the primary function of frataxin 17, 18 The nonconservative W168R mutation would change an aromatic, nonpolar tryptophan to a basic, electrically charged arginine at amino acid position 168, on Beta-sheet 5 of the human FXN crystal structure. Here, we present a patient who carries the novel W168R missense mutation and 1133 expanded GAA repeats, leading to an especially severe phenotype.
Methods

Transfection and immunostaining
FXN
W168R was created using Addgene XL Site-Directed Mutagenesis Kit and primers to pcDNA3.1-hFrataxin-HA (Plasmid #31895). Human Embryonic Kidney (HEK) cells were co-transfected with 4 lg of FXN and mitoGFP cDNA via Lipofectamine 2000 reagent. Twenty-four hours after transfection, cells were fixed with 4% Paraformaldehyde followed by treatment with blocking buffer containing 5% normal goat serum, 3% Triton X-100, and 1% BSA. Primary antibody to the HA epitope was added at a 1:1000 dilution overnight. Alexa Fluora 568 secondary antibody was added at a dilution of 1:1000 and cells were imaged by confocal microscopy.
Transfection, subcellular fractionation, and western blot
Following transfection of FXN mutants, HEK cells were centrifuged at 150g to collect whole cell lysates. The soluble mitochondria fraction and insoluble mitochondria pellet were collected using Thermo Scientific Mitochondria Isolation Kit for Mammalian Cells (#89874). Protein concentration of each fraction was determined using BCA Protein Assay and each fraction was loaded on a 12% NuPage Gel for electrophoresis, followed by transfer to nitrocellulose membranes. Membranes were blocked with 3% Milk for 1 h and incubated with primary HA-antibody overnight at 4°C. Membranes were then incubated with secondary HRP-conjugated antibody for 1 h and immunoreactive bands were visualized using luminolenhanced chemiluminescence (ECL) HRP substrate.
MG132 treatment
HEK cells were transfected with FXN
WT and FXN W168R mutants via Lipofectamine 2000 reagent. Twenty-four hours after transfection cells were treated with 10 lmol/L MG132 for 5 h followed by cell lysis. Equal amounts of total lysate were loaded on a 12% NuPage gel.
Quantification and statistical analysis
Image J Software was used to quantify FXN levels on western blots and is represented as mean AE SEM. Twotailed student's t-test was used to compare FXN W168R to FXN WT . Significance was set at P < 0.05. Image J software was also used to calculate Pearson's correlation coefficient for quantification of co-localization in immunofluorescence images.
Results
Case history
A 6-year-old boy evaluated for ataxia, was historically smaller in size and slower to progress developmentally than his fraternal twin brother. His height and weight were consistently below the first percentile since birth. Hypotonia, decreased stamina, clumsiness, and balance difficulties were noted around age two. When symptoms failed to improve by age three, orthotics were prescribed, and physical therapy was initiated. At age four, he was diagnosed with mild concentric left ventricular hypertrophy, diastolic dysfunction as well as a scoliosis of 14°. Initial testing included standard blood work, a brain MRI, and ophthalmologic evaluation. Whole exome sequencing performed to identify mitochondrial diseases and other neurodegenerative disorders ultimately rendered a diagnosis of Friedreich ataxia with GAA repeats of 19 and 1133 and a novel W168R missense mutation. The subject's father carried this mutation and his mother carried an expanded GAA repeat. With time, he continued to progress and has failed to gain fully independent walking. At age 8 he developed new onset type I diabetes. His echo cardiogram reveals thickened ventricular septum (Z score >9), and his scoliosis progressed to a curvature. . . to, and his ambulatory ability decreased as he became wheel chair bound. immunoreactivity (Fig. 1A) . To determine the effects of the W168R missense mutation on FXN import into the mitochondria, the FXN W168R variant containing a C-terminal HA tag was co-transfected with mitoGFP in Human Embryonic Kidney (HEK 293) cells. Confocal microscopy images with an antibody to the hemagglutinin epitope, to detect exogenous FXN only, show FXN W168R co-localization with mitoGFP, but with lower levels of FXN immunoreactivity compared to FXN WT (Fig. 2) . These data suggests that although W168R decreases mature FXN levels, the immunoreactivity that remains still can associate with mitochondria. In addition, FXNW168R co-immunoprecipitates more readily with mitochondrial processing peptidase (MPP) compared to FXN WT showing enhanced interactions of with the FXN W168R-42-210 form (Fig. 1B) . Similarly, the FXN 42-210 form of W168R is present in both soluble and insoluble mitochondria fractions (Fig. 1C) (Fig. 1D ). This suggests that increasing mature FXN levels for FXN W168R will require alternative approaches to repair FXN processing from intermediate to mature form.
W168R impairs
Discussion
This work identifies W168R as a particularly severe pathogenic mutation in FRDA. This patient presented with an age of onset (2) much earlier than most childhood patients. Other individuals presenting at this age have sometimes had end stage cardiomyopathy in the absence of ataxia, distinct from the presentation of the present patient. 19 While the patient described here had a single long GAA repeat, the extremely early onset and significant progression demonstrates that the second mutation (W168R) also must lead to a severely deficient amount of functional frataxin. FXN 42-210 is the dominant form of FXN made from W168R, with production of almost no detectable amounts of FXN 81-210. G130V also predominantly leads to production of FXN 42-210 with very low levels of FXN but is associated with a mild phenotype. The small amount of fully processed FXN 81-210 produced from G130V may be sufficient to ameliorate the phenotype in a way that the extreme processing defect of W168R does not. Alternatively, W168R may also have another dysfunctional feature beyond abnormal processing that leads to a more severe phenotype. The W168R mutation occurs one alpha helix turn away from R165C, a mutation associated with abnormalities in the cysteine desulturase binding and ironsulfur chaperoning activity of frataxin. Conceivably, W168R may also have impaired functionality, and phenotypic differences related to W168R mutations may also reflect abnormalities in addition to processing differences from wild type frataxin. Thus amelioration of the dysfunction associated with W168R will require approaches to overcome abnormal processing (e.g., enhancement of MPP binding) and potentially methods for restoring function to W168R once its activity is able to be defined.
